These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 32343642)

  • 1. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
    Mody R; Yu AL; Naranjo A; Zhang FF; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Hank JA; Felder M; Birstler J; Sondel PM; Asgharzadeh S; Glade-Bender J; Katzenstein H; Maris JM; Park JR; Bagatell R
    J Clin Oncol; 2020 Jul; 38(19):2160-2169. PubMed ID: 32343642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.
    Lerman BJ; Li Y; Carlowicz C; Granger M; Cash T; Sadanand A; Somers K; Ranavaya A; Weiss BD; Choe M; Foster JH; Pinto N; Morgenstern DA; Rafael MS; Streby KA; Zeno RN; Mody R; Yazdani S; Desai AV; Macy ME; Shusterman S; Federico SM; Bagatell R
    J Clin Oncol; 2023 Jan; 41(3):508-516. PubMed ID: 36206505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.
    Erbe AK; Diccianni MB; Mody R; Naranjo A; Zhang FF; Birstler J; Kim K; Feils AS; Hung JT; London WB; Shulkin BL; Mathew V; Parisi MT; Servaes S; Asgharzadeh S; Maris JM; Park J; Yu AL; Sondel PM; Bagatell R
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Corbacioglu S; Lode H; Ellinger S; Zeman F; Suttorp M; Escherich G; Bochennek K; Gruhn B; Lang P; Rohde M; Debatin KM; Steinbach D; Beilken A; Ladenstein R; Spachtholz R; Heiss P; Hellwig D; Tröger A; Koller M; Menhart K; Riemenschneider MJ; Zoubaa S; Kietz S; Jakob M; Sommer G; Heise T; Hundsdörfer P; Kühnle I; Dilloo D; Schönberger S; Schwabe G; von Luettichau I; Graf N; Schlegel PG; Frühwald M; Jorch N; Paulussen M; Schneider DT; Metzler M; Leipold A; Nathrath M; Imschweiler T; Christiansen H; Schmid I; Crazzolara R; Niktoreh N; Cario G; Faber J; Demmert M; Babor F; Fröhlich B; Bielack S; Bernig T; Greil J; Eggert A; Simon T; Foell J
    Lancet Oncol; 2024 Jul; 25(7):922-932. PubMed ID: 38936379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain.
    Castañeda A; Gorostegui M; Miralles SL; Chamizo A; Patiño SC; Flores MA; Garraus M; Lazaro JJ; Santa-Maria V; Varo A; Muñoz JP; Mora J
    ESMO Open; 2022 Apr; 7(2):100462. PubMed ID: 35397431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.
    Bagatell R; London WB; Wagner LM; Voss SD; Stewart CF; Maris JM; Kretschmar C; Cohn SL
    J Clin Oncol; 2011 Jan; 29(2):208-13. PubMed ID: 21115869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
    Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
    Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
    Moreno L; Weston R; Owens C; Valteau-Couanet D; Gambart M; Castel V; Zwaan CM; Nysom K; Gerber N; Castellano A; Laureys G; Ladenstein R; Rössler J; Makin G; Murphy D; Morland B; Vaidya S; Thebaud E; van Eijkelenburg N; Tweddle DA; Barone G; Tandonnet J; Corradini N; Chastagner P; Paillard C; Bautista FJ; Gallego Melcon S; De Wilde B; Marshall L; Gray J; Burchill SA; Schleiermacher G; Chesler L; Peet A; Leach MO; McHugh K; Hayes R; Jerome N; Caron H; Laidler J; Fenwick N; Holt G; Moroz V; Kearns P; Gates S; Pearson ADJ; Wheatley K;
    J Clin Oncol; 2024 Apr; 42(10):1135-1145. PubMed ID: 38190578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
    Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
    Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
    Defachelles AS; Bogart E; Casanova M; Merks JHM; Bisogno G; Calareso G; Gallego Melcon S; Gatz SA; Le Deley MC; McHugh K; Probst A; Rocourt N; van Rijn RR; Wheatley K; Minard-Colin V; Chisholm JC
    J Clin Oncol; 2021 Sep; 39(27):2979-2990. PubMed ID: 34343032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.
    Cheung NK; Cheung IY; Kramer K; Modak S; Kuk D; Pandit-Taskar N; Chamberlain E; Ostrovnaya I; Kushner BH
    Int J Cancer; 2014 Nov; 135(9):2199-205. PubMed ID: 24644014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
    Shusterman S; Naranjo A; Van Ryn C; Hank JA; Parisi MT; Shulkin BL; Servaes S; London WB; Shimada H; Gan J; Gillies SD; Maris JM; Park JR; Sondel PM
    Clin Cancer Res; 2019 Oct; 25(20):6044-6051. PubMed ID: 31358541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?
    Raiser P; Schleiermacher G; Gambart M; Dumont B; Defachelles AS; Thebaud E; Tandonnet J; Pasqualini C; Proust S; Entz-Werle N; Aerts I; Ndounga-Diakou LA; Petit A; Puiseux C; Khanfar C; Rouger J; Mansuy L; Benadiba J; Millot F; Pluchart C; Laghouati S; Geoerger B; Vassal G; Valteau-Couanet D; Berlanga P
    Eur J Cancer; 2024 May; 202():114001. PubMed ID: 38489858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
    DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
    J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
    Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
    N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.
    DuBois SG; Mosse YP; Fox E; Kudgus RA; Reid JM; McGovern R; Groshen S; Bagatell R; Maris JM; Twist CJ; Goldsmith K; Granger MM; Weiss B; Park JR; Macy ME; Cohn SL; Yanik G; Wagner LM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Boucher N; Czarnecki S; Luo C; Tsao-Wei D; Matthay KK; Marachelian A
    Clin Cancer Res; 2018 Dec; 24(24):6142-6149. PubMed ID: 30093449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.
    Furman WL; McCarville B; Shulkin BL; Davidoff A; Krasin M; Hsu CW; Pan H; Wu J; Brennan R; Bishop MW; Helmig S; Stewart E; Navid F; Triplett B; Santana V; Santiago T; Hank JA; Gillies SD; Yu A; Sondel PM; Leung WH; Pappo A; Federico SM
    J Clin Oncol; 2022 Feb; 40(4):335-344. PubMed ID: 34871104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.
    Federico SM; McCarville MB; Shulkin BL; Sondel PM; Hank JA; Hutson P; Meagher M; Shafer A; Ng CY; Leung W; Janssen WE; Wu J; Mao S; Brennan RC; Santana VM; Pappo AS; Furman WL
    Clin Cancer Res; 2017 Nov; 23(21):6441-6449. PubMed ID: 28939747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.